Evidence map›Paper›PMID 30896267›Full record

ArticleDrug delivery2019

Poly(3-hydroxybutyrate-CO-3-hydroxyvalerate) PHBHV biocompatible nanocarriers for 5-FU delivery targeting colorectal cancer.

Ionut Cristian Radu, Ariana Hudita, Catalin Zaharia, Bianca Galateanu, Horia Iovu, Eugenia Vasile Tanasa, Sabina Georgiana Nitu, Octav Ginghina, Carolina Negrei, Aristidis Tsatsakis and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Ionut Cristian Radua Advanced Polymer Materials Group , University Politehnica of Bucharest , Bucharest , Romania.
Ariana Huditab Department of Biochemistry and Molecular Biology , University of Bucharest , Bucharest , Romania.
Catalin Zahariaa Advanced Polymer Materials Group , University Politehnica of Bucharest , Bucharest , Romania.
Bianca Galateanub Department of Biochemistry and Molecular Biology , University of Bucharest , Bucharest , Romania.ORCID http://orcid.org/0000-0001-8093-1750
Horia Iovua Advanced Polymer Materials Group , University Politehnica of Bucharest , Bucharest , Romania.
Eugenia Vasile Tanasac University Politehnica of Bucharest , Bucharest , Romania.
Sabina Georgiana Nitud National Research and Development Institute for Chemistry and Petrochemistry - ICECHIM , Bucharest , Romania.
Octav Ginghinae Department of Surgery , Sf. Ioan Emergency Clinical Hospital , Bucharest , Romania.
Carolina Negreig Department of Toxicology, Faculty of Pharmacy , Carol Davila University of Medicine and Pharmacy , Bucharest.
Aristidis Tsatsakish Department of Toxicology and Forensic Sciences, Faculty of Medicine , University of Crete , Heraklion , Greece.
Kelly Veloniai Department of Materials Science and Technology , University of Crete , Heraklion , Greece.
Mikhail Shtilmanj Department of Polymers , D.I. Mendeleyev University of Chemical Technology , Moscow , Russia.
Marieta Costacheb Department of Biochemistry and Molecular Biology , University of Bucharest , Bucharest , Romania.
Universitatea Națională de Știință și Tehnologie Politehnica București · ROUniversity of Bucharest · ROCarol Davila University of Medicine and Pharmacy · ROUniversity of Crete · GRD. Mendeleyev University of Chemical Technology of Russia · RUInstitutul Naţional de Cercetare Dezvoltare pentru Chimie si Petrochimie · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aiming to address the issue of poor bioavailability of most anti-tumor medicines against colorectal cancer, we developed a targeted anticancer nanocarrier using biocarriers able to both bind and easily release their load in a controlled manner. Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) carriers were obtained via the emulsification-diffusion method, loaded with 5-fluorouracil and then characterized in terms of particle morphology and size (SEM, DLS), drug uptake and release. The cytotoxic potential of the 5-fluorouracil-loaded polymer nanocarriers on human adenocarcinoma cells (HT-29 cell line) was investigated. The in vitro studies clearly demonstrated that while the nanocarriers themselves slightly alter HT-29 cell viability, when loaded with 5-fluorouracil they significantly decrease cell viability, suggesting that the polymer itself exhibits low cytotoxicity and the drug-loaded carrier acts in an efficient manner to kill HT-29 human adenocarcinoma cells.

Indexed as

AdenocarcinomaAntimetabolites, AntineoplasticBiological AvailabilityCell SurvivalColorectal NeoplasmsDrug CarriersDrug Delivery SystemsDrug LiberationFluorouracilHT29 CellsHumansMicroscopy, Electron, ScanningNanoparticlesParticle SizePolyestersPolyhydroxybutyratesAntimetabolites, AntineoplasticDrug CarriersFluorouracilpoly(3-hydroxybutyrate)-co-(3-hydroxyvalerate)PolyestersPolyhydroxybutyratesPolymers5-FUanticancer efficacycolorectal cancerHT-29Nanocarrierpolyhydroxyalkanoate

Identifiers

PMID30896267
PMCPMC6442118
OpenAlexW2924249867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.